TCRX
TScan Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.17
close · 2026-10-30
value
8
cheaper than peers8
quality
4
stronger fundamentals4
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.17× | 98 |
| price to sales | 1.66× | 91 |
| earnings yield, 2 years ago | -779.4% | 2 |
| earnings yield, 1 year ago | -653.3% | 2 |
| earnings yield, latest year | -573.1% | 2 |
| cash flow yield, 3 years ago | -598.0% | 1 |
| cash flow yield, 2 years ago | -545.4% | 0 |
| cash flow yield, 1 year ago | -969.3% | 0 |
8 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -95.8% | 26 |
| debt to equity | 131.7% | 18 |
| revenue growth | -65.8% | 13 |
| operating margin | -2901.3% | 8 |
4 of 4 measures available
Facts
| market cap | $12M |
| free cash flow | -$79.9M |
| employees | 138 |
| first trade | 2021-07-16 |
| next earnings | not reported |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.00 | -1.14 | -1.36 | -2.75 |
| free cash flow | -$139.7M | -$114.6M | -$64.5M | -$70.7M |
| net income | -$129.8M | -$127.5M | -$89.2M | -$66.2M |
| revenue | $10.3M | $2.8M | $21.0M | $13.5M |
| unusual items | $0 | -$1.1M | $0 | not reported |